Validated, Scalable, and Launch-Ready: Heelios Proof & Traction Clinical & IP Foundation

Heelios-owned footwear-specific U.S. Provisional Patent Application filed — full utility filing in progress.

194-patient double-blind trials + 45k post-market devices show 3× circulation boost and 81% improved comfort.

Zero adverse events; HSA/FSA eligible.

Strategic interest: Generating strong inbound interest from major international footwear brands across performance and fashion segments.

Tier-1 manufacturer on standby for 500k+ unit ramp.

Pre-revenue with blue-chip pipeline — ready for global rollout.

Investor/Partner Signals

In 2025's footwear frenzy, Heelios offers 5–10x ROI potential via wellness disruption.